IFNB1 and non-small cell lung carcinoma: Of note, IFNβ plasma levels in Dox-treated YUMM5.2 Ifnb1eGFP-bearing mice of approx. 4 pg/mL (Fig. 1E) were comparable to concentrations detectable in serum of non-small cell lung cancer (NSCLC) patients with brain metastases after radiotherapy and prior to complete or partial response to combined radiotherapy and immune checkpoint inhibition using ipilimumab, which ranged from approximately 4 to maximum 20 pg/mL (27).